Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Operating Leases (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Leases for 7 consecutive years, with $66.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 64.81% to $66.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.8 million through Dec 2025, down 64.81% year-over-year, with the annual reading at $66.8 million for FY2025, 64.81% down from the prior year.
  • Operating Leases for Q4 2025 was $66.8 million at Intellia Therapeutics, down from $70.6 million in the prior quarter.
  • The five-year high for Operating Leases was $190.0 million in Q4 2024, with the low at $34.8 million in Q1 2021.
  • Average Operating Leases over 5 years is $85.5 million, with a median of $81.5 million recorded in 2024.
  • The sharpest move saw Operating Leases skyrocketed 376.71% in 2021, then crashed 64.81% in 2025.
  • Over 5 years, Operating Leases stood at $64.9 million in 2021, then skyrocketed by 75.65% to $114.0 million in 2022, then decreased by 15.15% to $96.7 million in 2023, then soared by 96.34% to $190.0 million in 2024, then plummeted by 64.81% to $66.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $66.8 million, $70.6 million, and $75.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.